Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 5:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 79,410 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)

NCT02597634
View directory record Official record
Conditions
Delayed Onset Muscle Soreness, DOMS
Interventions
SST-0225, Placebo
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Hollywood, Florida • South Miami, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 13, 2016 · Synced Nov 13, 2026, 5:43 AM EST
Active, not recruiting Not applicable Interventional

Harmony & Health: Feasibility of a Movement Intervention to Improve Psychosocial Wellbeing in Black Adults in Northeast Texas

NCT05761964
View directory record Official record
Conditions
Psychological
Interventions
Harmony & Health, Health Education
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 13, 2026, 5:43 AM EST
Recruiting Not applicable Interventional

Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

NCT04748809
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Diet 1, Diet 2
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 2 Interventional

Pycnogenol for the Treatment of Lymphedema

NCT00214032
View directory record Official record
Conditions
Lymphedema
Interventions
Pycnogenol, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Nov 13, 2026, 5:43 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Flow-Restorative Yoga to Decrease Pain and Inflammation

NCT03790098
View directory record Official record
Conditions
Pain, Inflammation
Interventions
Restorative-Flow Yoga
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 13, 2026, 5:43 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

NCT03598998
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions
Pembrolizumab, Pralatrexate
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

NCT03293498
View directory record Official record
Conditions
Influenza
Interventions
NanoFlu, Fluzone HD - Day 0, Fluzone HD - Day 21, Saline - Day 21
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
60 Years and older
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Raleigh, North Carolina • Rocky Mount, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Nov 13, 2026, 5:43 AM EST
Terminated Phase 2 Interventional Results available

TPI 287 in Patients With Recurrent Glioblastoma Multiforme

NCT01113463
View directory record Official record
Conditions
Brain Cancer
Interventions
TPI 287
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Nov 13, 2026, 5:43 AM EST
Completed No phase listed Observational

Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer

NCT05255393
View directory record Official record
Conditions
Cervical Cancer, Vulvar Cancer
Interventions
Questionnaires
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 2 Interventional Results available

First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib

NCT01289821
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Nov 13, 2026, 5:43 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Electronic Cigarettes vs Combustible Cigarettes and Nicotine Gum

NCT02269514
View directory record Official record
Conditions
Smoking
Interventions
Own Brand Cigarette, Electronic Cigarette #1, Electronic Cigarette #2, Electronic Cigarette #3, Leading U.S. Nicotine Gum
Other
Lead sponsor
R.J. Reynolds Vapor Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Nov 13, 2026, 5:43 AM EST
Completed Not applicable Interventional Results available

Learn to Quit-HIV Pilot Study

NCT04609514
View directory record Official record
Conditions
HIV/AIDS, Smoking Cessation, Tobacco Use Disorder
Interventions
Learn to Quit-HIV, QuitGuide, Nicotine patch, Smartphone coaching
Device · Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Nov 13, 2026, 5:43 AM EST
Recruiting Not applicable Interventional

Studying How Outpatient Water affEcts Risks With Drains (SHOWER Study)

NCT04725916
View directory record Official record
Conditions
Postoperative Wound Infection, Postoperative Complications, Surgical Site Infection, Drain Site Complication
Interventions
Showering, Restriction of Showering
Other
Lead sponsor
Sean Devitt
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 13, 2026, 5:43 AM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

NCT00136916
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Insulin, Subcutaneous insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 75 Years
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
69
States / cities
Phoenix, Arizona • Tucson, Arizona • Fresno, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2010 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 3 Interventional

Investigation of a Novel Positive Pressure Therapy to Rescue Patients Failing to Tolerate CPAP During an Initial Encounter

NCT00635206
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
BiPap auto with Fi Flex, Standard CPAP
Device
Lead sponsor
Clayton Sleep Insititute
Industry
Eligibility
21 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 14, 2009 · Synced Nov 13, 2026, 5:43 AM EST
Not listed Not applicable Interventional

Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study

NCT00870714
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel, Ketoconazole
Drug
Lead sponsor
Kansas City Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Nov 13, 2026, 5:43 AM EST
Not yet recruiting Phase 3 Interventional Accepts healthy volunteers

Effectiveness of Toothpaste Tablets on Plaque, Gingival Health and Caries Experiences

NCT07124533
View directory record Official record
Conditions
Gingival Inflammation, Dental Caries
Interventions
Toothpaste Tablet, Conventional Toothpaste
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 2 Interventional

Clinical Trial To Evaluate ANT-1207 In Subjects With Acne

NCT01293552
View directory record Official record
Conditions
Acne Vulgaris
Interventions
ANT-1207, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Miami, Florida • West Palm Beach, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults

NCT02674347
View directory record Official record
Conditions
Healthy Subjects
Interventions
3 g or 6 g Zidebactam, Placebo
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Nov 13, 2026, 5:43 AM EST
Completed Not applicable Interventional

Trial Comparing Different Stimulation Paradigms in Patients Treated With Vagus Nerve Stimulation for Refractory Epilepsy

NCT00782249
View directory record Official record
Conditions
Epilepsy
Interventions
Vagus nerve stimulation paradigm #1, Vagus nerve stimulation paradigm #2, Vagus nerve stimulation paradigm #3
Procedure
Lead sponsor
University Hospital, Ghent
Other
Eligibility
16 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 1 Interventional

Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

NCT00334438
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, yttrium Y 90 ibritumomab tiuxetan, Indium 111 ibritumomab tiuxetan
Biological · Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Hackensack, New Jersey • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 2 Interventional Results available

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

NCT04146038
View directory record Official record
Conditions
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Salsalate, Venetoclax
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01595438
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sylmar, California • Royal Oak, Michigan • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Nov 13, 2026, 5:43 AM EST
Completed Phase 4 Interventional Results available

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

NCT00312338
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
VIGAMOX
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year to 13 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2012 · Synced Nov 13, 2026, 5:43 AM EST